{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:10:48Z","timestamp":1793077848604,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111227","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:58:55Z","timestamp":1761263935000},"page":"111227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC)"],"prefix":"10.1016","volume":"214","author":[{"given":"Vincent","family":"Gr\u00e9goire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5374-9558","authenticated-orcid":false,"given":"Johannes","family":"Kaanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6369-9742","authenticated-orcid":false,"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Vulquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5540-4796","authenticated-orcid":false,"given":"Sandra","family":"Nuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Doornaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-3193","authenticated-orcid":false,"given":"Jan","family":"Alsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0814-8179","authenticated-orcid":false,"given":"Jens","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111227_b0005","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0015","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","article-title":"Hypoxic radiosensitization: adored and ignored","volume":"25","author":"Overgaard","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.radonc.2011.03.004","article-title":"Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck -a systematic review and meta-analysis","volume":"100","author":"Overgaard","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","article-title":"Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis","volume":"22","author":"Petit","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/CLEP.S103591","article-title":"The danish Head and Neck Cancer database","volume":"8","author":"Overgaard","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.radonc.2025.111227_b0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrc.2016.18","article-title":"Radiation oncology in the era of precision medicine","volume":"16","author":"Baumann","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2025.111227_b0040","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0959-8049(17)30416-1","article-title":"Improving radiotherapy of squamous cell carcinoma of the head and neck (HNSCC) through a continuous process of biological based clinical trials \u2212 a 40-year experience from the danish Head and Neck Cancer Group \u2013 DAHANCA","volume":"72","author":"Overgaard","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111227_b0045","doi-asserted-by":"crossref","unstructured":"Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28:2989-95. doi: 10.1200\/JCO.2009.27.4449.","DOI":"10.1200\/JCO.2009.27.4449"},{"key":"10.1016\/j.radonc.2025.111227_b0050","unstructured":"Overgaard J.Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6:509-18. 0965-0407(94)00075-1."},{"key":"10.1016\/j.radonc.2025.111227_b0055","doi-asserted-by":"crossref","unstructured":"Overgaard, J., Hansen, H.S., Lindel\u00f8v, B., Overgaard, M., J\u00f8rgensen, K., Rasmusson, B. Et al. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. 20 (Suppl. 1): 143\u2013149, 1991.","DOI":"10.1016\/0167-8140(91)90202-R"},{"key":"10.1016\/j.radonc.2025.111227_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","article-title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5\u201385","volume":"46","author":"Overgaard","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0065","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(03)14361-9","article-title":"Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial","volume":"362","author":"Overgaard","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111227_b0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ijrobp.2023.11.055","article-title":"NIMRAD Trial Group. Randomized phase 3 Trial of the Hypoxia Modifier Nimorazole added to Radiation Therapy with Benefit Assessed in Hypoxic Head and Neck Cancers Determined using a Gene Signature (NIMRAD)","volume":"119","author":"Thomson","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111227_b0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2015.04.005","article-title":"IAEA-HypoX. a randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma","volume":"116","author":"Hassan Metwally","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0080","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/0284186X.2014.992547","article-title":"Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. results from the DAHANCA 18 phase II study","volume":"54","author":"Bentzen","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110899","article-title":"DAHANCA19: a randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck","volume":"208","author":"Eriksen","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.radonc.2017.10.018","article-title":"Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project","volume":"126","author":"Lassen","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110373","article-title":"De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: who, why, what, where, when, how, how much\u2026and what next?","volume":"200","author":"Chen","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.radonc.2013.06.011","article-title":"Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells","volume":"108","author":"S\u00f8rensen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2009.10.008","article-title":"Danish Head and Neck Cancer Group (DAHANCA). HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer","volume":"94","author":"Lassen","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0115","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-11-1182","article-title":"Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer","volume":"71","author":"Toustrup","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.111227_b0120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.radonc.2011.09.010","article-title":"Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck","volume":"102","author":"Toustrup","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110348","article-title":"Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer","volume":"199","author":"Besso","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0130","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12967-023-04439-2","article-title":"Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts","volume":"21","author":"Koi","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.radonc.2025.111227_b0135","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2025.111227_b0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111227_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2019.01.018","article-title":"Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update","volume":"134","author":"Biau","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2017.10.016","volume":"126","author":"Gr\u00e9goire","year":"2018","journal-title":"TROG consensus guidelines Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0155","doi-asserted-by":"crossref","unstructured":"Gr\u00e9goire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, doi:10.1016\/j.radonc.2013.10.010.","DOI":"10.1016\/j.radonc.2013.10.010"},{"key":"10.1016\/j.radonc.2025.111227_b0160","first-page":"5","article-title":"Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT): Contents","volume":"10","author":"The international commission on radiation units and measurements","year":"2010","journal-title":"J ICRU"},{"key":"10.1016\/j.radonc.2025.111227_b0165","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.radonc.2017.04.019","article-title":"Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV\/p16 negative squamous cell carcinoma of the head and neck: results of the benchmark case procedure","volume":"123","author":"Christiaens","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0170","article-title":"Radiotherapy quality assurance of the prospective randomised EORTC-1219\/DAHANCA-29 trial: an individual case review analysis","volume":"21","author":"Alyamani","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111227_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2025.111227_b0180","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/0360-3016(84)90545-5","article-title":"A phase I clinical study of Nimorazole as a hypoxic radiosensitizer","volume":"10","author":"Timothy","year":"1984","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111227_b0185","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3109\/0284186X.2013.864050","article-title":"Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC)","volume":"53","author":"Metwally","year":"2014","journal-title":"Acta Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:26:09Z","timestamp":1786537569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"alternative-id":["S0167814025052314"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111227","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111227"}}